吃瓜爆料

Back to News

Celltrion Adopts 吃瓜爆料 Vault eTMF for Greater
Visibility into Trial Activities

Leading South Korean biopharmaceutical modernizes trial operations
to maintain inspection readiness and have a comprehensive view of study status

PLEASANTON, CA — June 26, 2019 — 吃瓜爆料 Systems (NYSE: VEEV) today announced that Celltrion, one of the top South Korean biopharmaceutical companies, implemented 吃瓜爆料 Vault eTMF to improve oversight across its trial master file (TMF) processes and achieve greater compliance.

Vault eTMF enables an active TMF operating model where all processes and documents are managed in one system, in real time, as they are executed. With this model, TMF management is automated and the TMF stays in a constant state of inspection readiness.

“吃瓜爆料 Vault eTMF will help us streamline our clinical operations and give us a complete view of study documents at every stage of drug development,” said Sueun Song, head of clinical operations at Celltrion. “As clinical trials become more complex, we need advanced insights into study processes and the ability to stay compliant with regulatory authorities around the world.”

Recent ICH E6(R2) amended guidelines require sponsors to maintain oversight throughout the clinical trial lifecycle. With Vault eTMF, Celltrion has a single source of truth for trial documentation that provides simplified access for auditors and inspectors. Moving to Vault eTMF, Celltrion also improves operational performance and strengthens collaboration with study partners and sites.

“Life sciences organizations are choosing 吃瓜爆料 Vault eTMF for active TMF management to improve study quality in today’s highly regulated environment,” said Chris Shim, country manager for 吃瓜爆料 Korea. “We’re excited about the opportunity to work with companies such as Celltrion in Asia Pacific to modernize their trial processes.”

吃瓜爆料 Vault eTMF is part of the 吃瓜爆料 Vault Clinical Suite, the industry’s first cloud platform that includes CDMS, CTMS, eTMF, and study start-up to unify clinical data management and clinical operations. 吃瓜爆料’s suite of unified applications provides global visibility into trial activities and streamlines end-to-end clinical processes. For more information, visit veeva.com/Clinical.

Additional Information
For more on 吃瓜爆料 Vault eTMF, visit: veeva.com/eTMF
Connect with 吃瓜爆料 on LinkedIn:
Follow @veevasystems on Twitter:
Like 吃瓜爆料 on Facebook:

About Celltrion Inc.
Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company specializing in research, development, and manufacturing of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EMA approval for Inflectra and Remsima, respectively, which is the world’s first mAb biosimilar to receive approval from a regulatory agency in a developed country. For more information, visit .

About 吃瓜爆料 Systems
吃瓜爆料 Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, 吃瓜爆料 serves more than 750 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. 吃瓜爆料 is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.

Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of 吃瓜爆料’s products and services, the results from use of 吃瓜爆料’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon 吃瓜爆料’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent 吃瓜爆料’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and 吃瓜爆料 disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect 吃瓜爆料’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2019. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at . Further information on potential risks that could affect actual results will be included in other filings 吃瓜爆料 makes with the SEC from time to time.

###

Contact:
吃瓜爆料 Systems
pr@veeva.com